News Sentiment

AKTX sentiment intelligence

Akari Therapeutics PLC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 13.88 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

85/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+33.3% over one week, +3.6% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

Form 4 Akari Therapeutics PLC For: 17 July By Investing.com

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 85/100 classification
One-week reaction 33.3% Price confirming higher
Trend fit Trend active 3.6% over four weeks
Fair value -79.9% Below fair value
Market Dynamics buy signal Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 35
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 15
Market source 8
Investing.com Canada 4
Quartr 3
GlobeNewswire 3
TradingView 3
simplywall.st 3
Stocktwits 2

Event Lens

What the news is about

Classified themes
Market update 38
Earnings 13
Regulatory and legal 3
Deals and strategy 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 56
Stock Titan Direct company coverage

Akari Therapeutics (AKTX) director exercises pre-funded warrants for 22,474 ADSs

Akari Therapeutics director Samir Rashmikant Patel, through PranaBio Investments LLC, exercised pre-funded warrants on July 7, 2026, to acquire 22,474 American Depositary Shares (ADSs). These exercises involved different price points ($0.0004 and $8.00 per ADS) and were not part

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 09:40
Source
Stock Titan
Quartr Direct company coverage

Akari Therapeutics (AKTX) Q4 2025 earnings summary

Akari Therapeutics (AKTX) reported a Q4 2025 summary highlighting its strategic shift to next-generation antibody-drug conjugates (ADCs) following the acquisition of Peak Bio. The company's lead candidate, AKTX-101, is in preclinical development with a projected Phase 1 trial sta

Tone
Negative 25/100
Event
Deals and strategy
Published
16 Jul 2026 13:40
Source
Quartr
Quartr Direct company coverage

Akari Therapeutics (AKTX) Proxy filing Summary

Akari Therapeutics has released a summary of its upcoming 2026 Annual General Meeting (AGM), scheduled for June 30, 2026. The meeting will address 18 resolutions covering financial, governance, compensation, and capital matters, with the Board unanimously recommending a "for" vot

Tone
Negative 38/100
Event
Market update
Published
16 Jul 2026 04:11
Source
Quartr
Quartr Direct company coverage

Akari Therapeutics (AKTX) Q1 2026 earnings summary

Akari Therapeutics (AKTX) reported a Q1 2026 net loss of $14.5 million, significantly higher than Q1 2025 due to non-cash impairment charges. The company is focused on advancing its lead ADC program, AKTX-101, towards a Phase 1 trial by mid-2027 but faces substantial doubt about

Tone
Negative 10/100
Event
Earnings
Published
16 Jul 2026 03:11
Source
Quartr
Stock Titan Direct company coverage

[EFFECT] Akari Therapeutics Plc SEC Filing

Akari Therapeutics Plc (AKTX) has had an [EFFECT] SEC Filing, indicating the effectiveness of its S-3 shelf registration statement. This filing, accepted by EDGAR on July 14, 2026, and effective on July 13, 2026, allows the company flexibility in future offerings. The filing's se

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 01:11
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form S-3/A Akari Therapeutics PLC For: 10 July By Investing.com

This article announces the filing of Form S-3/A by Akari Therapeutics PLC on July 10. It is a brief, one-line report from Investing.com, providing basic information about the SEC filing. The article does not contain further details about the content of the S-3/A filing.

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 00:09
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Akari Therapeutics (NASDAQ: AKTX) files to register 5.99M ADSs from May 2026 private placement

Akari Therapeutics Plc (NASDAQ: AKTX) has filed an amended shelf registration to allow existing holders to resell up to 5.99 million American Depositary Shares (ADSs), representing approximately 479.99 billion ordinary shares. These ADSs originate from a private placement in May

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

Akari Therapeutics (NASDAQ: AKTX) adds private‑placement warrants and purchase agreement exhibits

Akari Therapeutics (NASDAQ: AKTX) has amended its S-3 registration statement to file exhibits, including amended Articles of Association, deposit agreement documents for American Depositary Shares, various warrant forms (Pre-Funded, Series H, I, and J), and the Securities Purchas

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 20:10
Source
Stock Titan
GlobeNewswire Direct company coverage

Akari Therapeutics Appoints Former AACR President and

Akari Therapeutics has appointed Patricia LoRusso, D.O., a renowned oncology drug development leader and former AACR President, to its Scientific Advisory Board. Dr. LoRusso's extensive experience in early-phase oncology clinical development will be instrumental as Akari advances

Tone
Positive 74/100
Event
Market update
Published
07 Jul 2026 22:49
Source
GlobeNewswire
FinanzNachrichten.de Direct company coverage

Akari Therapeutics Plc: Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board

Akari Therapeutics, an oncology biotechnology company, announced the appointment of Patricia LoRusso, D.O., a renowned oncology drug development leader and former AACR President, to its Scientific Advisory Board. Dr. LoRusso's extensive experience in early-phase clinical developm

Tone
Positive 73/100
Event
Market update
Published
07 Jul 2026 13:09
Source
FinanzNachrichten.de
GlobeNewswire Direct company coverage

Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board

Akari Therapeutics, an oncology biotechnology company, has appointed Dr. Patricia LoRusso, a globally recognized leader in oncology drug development, to its Scientific Advisory Board. Dr. LoRusso's extensive expertise will be crucial as Akari advances its lead candidate, AKTX-101

Tone
Positive 71/100
Event
Market update
Published
07 Jul 2026 12:41
Source
GlobeNewswire
Stocktwits Direct company coverage

AKTX Stock Goes Parabolic After Hours On $5.5M Capital Raise, Cancer Data Win: Wall Street Sees 400% Upside

Akari Therapeutics (AKTX) shares surged over 133% after reporting positive preclinical data for its lead cancer therapy, AKTX-101, and announcing a $5.5 million private placement. AKTX-101 showed strong results in pancreatic cancer cells when combined with an existing drug. The c

Tone
Positive 72/100
Event
Earnings
Published
07 Jul 2026 11:09
Source
Stocktwits
Stock Titan Direct company coverage

Akari Therapeutics (NASDAQ: AKTX) AGM OKs new share issuances and board changes

Akari Therapeutics shareholders approved several key proposals at their June 30, 2026 Annual General Meeting, including the 2025 financial statements, most director re-elections, and the appointment of auditors. Critically, shareholders also approved significant equity-related it

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 21:41
Source
Stock Titan
Investing.com Canada Direct company coverage

Form S-3 Akari Therapeutics PLC For: 2 July By Investing.com

Akari Therapeutics PLC filed a Form S-3 on July 2nd. The article provides the filing information and mentions that the company's stock symbol is AKTX, which was up 1.56% at the time of publication. The content itself seems to be a template for financial news with many market data

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 21:41
Source
Investing.com Canada
Stock Titan Direct company coverage

Akari Therapeutics (NASDAQ: AKTX) registers 5,999,999 ADSs, 80,000-shares each

Akari Therapeutics (NASDAQ: AKTX) has registered 5,999,999 American Depositary Shares (ADSs), representing 479,999,920,000 ordinary shares, for resale by selling shareholders. These ADSs arise from a May 2026 private placement and include shares issuable upon the exercise of vari

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 21:09
Source
Stock Titan
Bitget Direct company coverage

Akari Therapeutics PLC has filed a prospectus supplement with the U.S. Securities and Exchange Commission (SEC)

Akari Therapeutics PLC has filed a prospectus supplement with the SEC concerning the resale of up to 6 million American Depositary Shares (ADS) by existing shareholders. These ADS represent up to 48 billion ordinary shares. The company will not receive any proceeds from this tran

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 09:11
Source
Bitget
The Manila Times Direct company coverage

Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones

Akari Therapeutics announced the completion of its $5.5 million PIPE early by consolidating remaining funding tranches, along with an additional $2.8 million from warrant exercises, totaling approximately $8.3 million in Q2 2026. This capital injection strengthens the company's f

Tone
Positive 81/100
Event
Regulatory and legal
Published
30 Jun 2026 08:39
Source
The Manila Times
Investing.com Direct company coverage

Akari Therapeutics completes $8.3m capital raise in Q2

Akari Therapeutics Plc (NASDAQ:AKTX) successfully completed a private placement and warrant exercises, raising approximately $8.3 million in total capital during the second quarter of 2026. This capital infusion is significant for the oncology biotechnology company, which is deve

Tone
Positive 71/100
Event
Earnings
Published
30 Jun 2026 08:09
Source
Investing.com
Finviz Direct company coverage

AKTX - Akari Therapeutics Plc ADR Options

This article provides a detailed financial overview of Akari Therapeutics Plc (AKTX), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as EPS, sales growth, insider and institutiona

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 20:41
Source
Finviz
GlobeNewswire Direct company coverage

Akari Therapeutics Completes Previously Announced PIPE,

Akari Therapeutics announced the completion of its $5.5 million PIPE combined with an additional $2.8 million from warrant exercises, totaling $8.3 million in Q2 2026. This funding strengthens the company's balance sheet, supporting the advancement of its lead candidate AKTX-101

Tone
Positive 70/100
Event
Market update
Published
29 Jun 2026 13:12
Source
GlobeNewswire
Investing.com Canada Direct company coverage

Akari Therapeutics completes $8.3m capital raise in Q2 By Investing.com

Akari Therapeutics (NASDAQ: AKTX) has successfully completed an $8.3 million capital raise in Q2 2026, comprising a $5.5 million private investment in public equity (PIPE) led by existing investors and $2.8 million from warrant exercises. This funding is critical for the oncology

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 13:12
Source
Investing.com Canada
Stock Titan Direct company coverage

Akari locks in $8.3M to fund cancer drug trial push

Akari Therapeutics announced the completion of an $8.3 million funding round in Q2 2026, comprising a $5.5 million PIPE and $2.8 million from warrant exercises. This capital infusion is intended to advance its lead drug candidate, AKTX-101, towards a Phase 1 clinical trial and pr

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 13:12
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form S-1/A Akari Therapeutics PLC For: 26 June By Investing.com

This article announces that Akari Therapeutics PLC filed a Form S-1/A on June 26. The news is brief and directly states the filing, indicating it's a financial regulatory update for the company. The article also includes various market data and related news not directly tied to t

Tone
Neutral 50/100
Event
Regulatory and legal
Published
27 Jun 2026 19:40
Source
Investing.com Nigeria